Literature DB >> 12197892

Atypical X-linked SCID phenotype associated with growth hormone hyporesponsiveness.

M V Ursini1, L Gaetaniello, R Ambrosio, E Matrecano, A J Apicella, M C Salerno, C Pignata.   

Abstract

Severe combined immunodeficiency (SCID) is a heterogeneous group of disorders characterized by defect of T- and B-cell immunity. In many cases of autosomal recessive SCID, thus far described, the molecular alteration involves genes encoding for molecules that participate in the signal transduction. We report on a patient affected by a combined immunodeficiency, characterized by severe T-cell functional impairment, in spite of a close to normal number of circulating mature type T and B cells. NK cells were absent. Associated with the immunodeficiency, this patient also showed short stature characterized by very low growth velocity, delayed bone age and absence of increase of the plasma levels of Insulin growth factor-I (IGF-I) after growth hormone (GH) in vivo stimulation indicating peripheral hyporesponsiveness to GH. Evaluation of the protein tyrosine phosphorylation events occurring following either T-cell receptor (TCR) or GH receptor (GHR) triggering revealed striking abnormalities. No molecular alteration of GHR gene was found, thus suggesting the presence of postreceptorial blockage. Mutational screening and expression analysis failed to reveal any molecular alteration of JAK2 and STAT 5 A/B genes thus ruling out the involvement of these genes in the pathogenesis of this form of SCID. Mutational analysis of IL2Rgamma chain gene revealed the presence of a L183S missense mutation, thus indicating an atypical and a more complex clinical presentation of this X-linked form of SCID. At our knowledge, this is the first report on the GH hyporesponsiveness in this disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12197892      PMCID: PMC1906458          DOI: 10.1046/j.1365-2249.2002.01823.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  31 in total

1.  Partial growth-hormone insensitivity: the role of growth-hormone receptor mutations in idiopathic short stature.

Authors:  A D Goddard; P Dowd; S Chernausek; M Geffner; J Gertner; R Hintz; N Hopwood; S Kaplan; L Plotnick; A Rogol; R Rosenfield; P Saenger; N Mauras; R Hershkopf; M Angulo; K Attie
Journal:  J Pediatr       Date:  1997-07       Impact factor: 4.406

Review 2.  Searching for genes involved in the pathogenesis of primary immunodeficiency diseases: lessons from mouse knockouts.

Authors:  C M Kokron; F A Bonilla; H C Oettgen; N Ramesh; R S Geha; F Pandolfi
Journal:  J Clin Immunol       Date:  1997-03       Impact factor: 8.317

3.  Jak2 is essential for signaling through a variety of cytokine receptors.

Authors:  E Parganas; D Wang; D Stravopodis; D J Topham; J C Marine; S Teglund; E F Vanin; S Bodner; O R Colamonici; J M van Deursen; G Grosveld; J N Ihle
Journal:  Cell       Date:  1998-05-01       Impact factor: 41.582

4.  Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis.

Authors:  H Neubauer; A Cumano; M Müller; H Wu; U Huffstadt; K Pfeffer
Journal:  Cell       Date:  1998-05-01       Impact factor: 41.582

Review 5.  Mechanism of signaling by growth hormone receptor.

Authors:  L S Argetsinger; C Carter-Su
Journal:  Physiol Rev       Date:  1996-10       Impact factor: 37.312

Review 6.  Naturally occurring primary deficiencies of the immune system.

Authors:  A Fischer; M Cavazzana-Calvo; G De Saint Basile; J P DeVillartay; J P Di Santo; C Hivroz; F Rieux-Laucat; F Le Deist
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

7.  An interleukin-2 receptor gamma chain mutation with normal thymus morphology.

Authors:  N Sharfe; M Shahar; C M Roifman
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

8.  Screening for mutations causing X-linked severe combined immunodeficiency in the IL-2R gamma chain gene by single-strand conformation polymorphism analysis.

Authors:  P A Clark; T Lester; S Genet; A M Jones; R Hendriks; R J Levinsky; C Kinnon
Journal:  Hum Genet       Date:  1995-10       Impact factor: 4.132

9.  Phenotype: genotype relationships in growth hormone insensitivity syndrome.

Authors:  K A Woods; F Dastot; M A Preece; A J Clark; M C Postel-Vinay; P G Chatelain; M B Ranke; R G Rosenfeld; S Amselem; M O Savage
Journal:  J Clin Endocrinol Metab       Date:  1997-11       Impact factor: 5.958

10.  Mutations of the growth hormone receptor in children with idiopathic short stature. The Growth Hormone Insensitivity Study Group.

Authors:  A D Goddard; R Covello; S M Luoh; T Clackson; K M Attie; N Gesundheit; A C Rundle; J A Wells; L M Carlsson
Journal:  N Engl J Med       Date:  1995-10-26       Impact factor: 91.245

View more
  7 in total

1.  Hypomorphic Janus kinase 3 mutations result in a spectrum of immune defects, including partial maternal T-cell engraftment.

Authors:  Federica Cattaneo; Mike Recher; Stefania Masneri; Sachin N Baxi; Claudia Fiorini; Francesca Antonelli; Christian A Wysocki; Jose G Calderon; Hermann Eibel; Angela R Smith; Francisco A Bonilla; Erdyni Tsitsikov; Silvia Giliani; Luigi D Notarangelo; Sung-Yun Pai
Journal:  J Allergy Clin Immunol       Date:  2013-02-04       Impact factor: 10.793

2.  Short stature in partially corrected X-linked severe combined immunodeficiency--suboptimal response to growth hormone.

Authors:  Suk See De Ravin; Elaine Shum; Kol A Zarember; Geoffrey Rezvani; Ron G Rosenfeld; Constantine A Stratakis; Harry L Malech
Journal:  J Pediatr Endocrinol Metab       Date:  2008-11       Impact factor: 1.634

3.  The IL-2RG R328X nonsense mutation allows partial STAT-5 phosphorylation and defines a critical region involved in the leaky-SCID phenotype.

Authors:  A Arcas-García; M Garcia-Prat; M Magallón-Lorenz; A Martín-Nalda; O Drechsel; S Ossowski; L Alonso; J G Rivière; P Soler-Palacín; R Colobran; J Sayós; M Martínez-Gallo; C Franco-Jarava
Journal:  Clin Exp Immunol       Date:  2020-01-19       Impact factor: 4.330

4.  Clinical Heterogeneity in two patients with Noonan-like Syndrome associated with the same SHOC2 mutation.

Authors:  Donatella Capalbo; Maria Giuseppa Scala; Daniela Melis; Giorgia Minopoli; Nicola Improda; Loredana Palamaro; Claudio Pignata; Mariacarolina Salerno
Journal:  Ital J Pediatr       Date:  2012-09-20       Impact factor: 2.638

5.  IL2RG hypomorphic mutation: identification of a novel pathogenic mutation in exon 8 and a review of the literature.

Authors:  Che Kang Lim; Hassan Abolhassani; Sofia K Appelberg; Mikael Sundin; Lennart Hammarström
Journal:  Allergy Asthma Clin Immunol       Date:  2019-01-05       Impact factor: 3.406

6.  Novel Hemizygous IL2RG p.(Pro58Ser) Mutation Impairs IL-2 Receptor Complex Expression on Lymphocytes Causing X-Linked Combined Immunodeficiency.

Authors:  Elina A Tuovinen; Juha Grönholm; Tiina Öhman; Sakari Pöysti; Raine Toivonen; Anna Kreutzman; Kaarina Heiskanen; Luca Trotta; Sanna Toiviainen-Salo; John M Routes; James Verbsky; Satu Mustjoki; Janna Saarela; Juha Kere; Markku Varjosalo; Arno Hänninen; Mikko R J Seppänen
Journal:  J Clin Immunol       Date:  2020-02-19       Impact factor: 8.317

7.  Case Report: Interleukin-2 Receptor Common Gamma Chain Defect Presented as a Hyper-IgE Syndrome.

Authors:  Brahim Belaid; Lydia Lamara Mahammed; Aida Mohand Oussaid; Melanie Migaud; Yasmine Khadri; Jean Laurent Casanova; Anne Puel; Nafissa Ben Halla; Reda Djidjik
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.